Abstract
Ustekinumab is currently being explored for the treatment of alopecia areata. Here, our work in a murine model and in human patients indicates that neutralization of the IL-12 and IL-23 pathways does not ameliorate disease.
Publication types
-
Letter
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alopecia / drug therapy
-
Alopecia / immunology*
-
Alopecia / pathology
-
Animals
-
Antibodies, Neutralizing / immunology
-
Antibodies, Neutralizing / pharmacology*
-
Female
-
Humans
-
Interleukin-12 Subunit p40 / antagonists & inhibitors*
-
Interleukin-12 Subunit p40 / immunology
-
Interleukin-23 Subunit p19 / antagonists & inhibitors*
-
Interleukin-23 Subunit p19 / immunology
-
Male
-
Mice
Substances
-
Antibodies, Neutralizing
-
IL12B protein, human
-
IL23A protein, human
-
Il12b protein, mouse
-
Il23a protein, mouse
-
Interleukin-12 Subunit p40
-
Interleukin-23 Subunit p19